Grifols (GIFLF) Restructuring Costs (2022 - 2023)
Grifols' (GIFLF) quarterly Restructuring Costs came in at $171022.8 in Q4 2023, up 364.68% on a YoY basis from $36804.4 in Q4 2022, and up 364.68% quarter-over-quarter from $36804.4 in Q4 2022.
Powered by 
Analysis
Grifols (GIFLF) Restructuring Costs (2022 - 2023) Analysis & Trends
Grifols (GIFLF) has reported Restructuring Costs for 2 consecutive years, with $171022.8 the latest figure, recorded in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |